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ORIGINAL ARTICLE
Altered emotionality and neuronal excitability in mice lacking
KCTD12, an auxiliary subunit of GABAB receptors associated
with mood disorders
F Cathomas1,2,5, M Stegen3,5, H Sigrist1, L Schmid1, E Seifritz2,4, M Gassmann3, B Bettler3 and CR Pryce1,4
Gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the brain, is fundamental to brain function and
implicated in the pathophysiology of several neuropsychiatric disorders. GABA activates G-protein-coupled GABAB receptors
comprising principal GABAB1 and GABAB2 subunits as well as auxiliary KCTD8, 12, 12b and 16 subunits. The KCTD12 gene has been
associated with bipolar disorder, major depressive disorder and schizophrenia. Here we compare Kctd12 null mutant (Kctd12− /−)
and heterozygous (Kctd12+/− ) with wild-type (WT) littermate mice to determine whether lack of or reduced KCTD12 expression
leads to phenotypes that, extrapolating to human, could constitute endophenotypes for neuropsychiatric disorders with which
KCTD12 is associated. Kctd12− /− mice exhibited increased fear learning but not increased memory of a discrete auditory-
conditioned stimulus. Kctd12+/− mice showed increased activity during the inactive (light) phase of the circadian cycle relative to
WT and Kctd12− /− mice. Electrophysiological recordings from hippocampal slices, a region of high Kctd12 expression, revealed an
increased intrinsic excitability of pyramidal neurons in Kctd12−/− and Kctd12+/− mice. This is the ﬁrst direct evidence for
involvement of KCTD12 in determining phenotypes of emotionality, behavioral activity and neuronal excitability. This study
provides empirical support for the polymorphism and expression evidence that KCTD12 confers risk for and is associated with
neuropsychiatric disorders.
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INTRODUCTION
Gamma-aminobutyric acid (GABA) is the major inhibitory neuro-
transmitter in the mammalian central nervous system, acting on
ionotropic GABAA and metabotropic GABAB receptors.
1 GABAB
receptors control neuronal activity throughout the brain by
regulating neurotransmitter release and gating of voltage-
sensitive Ca2+ and Kir3-type K+ channels. The principal subunits
GABAB1a, GABAB1b and GABAB2 form fully functional heteromeric
GABAB(1a,2) and GABAB(1b,2) receptors.
2 GABAB1a and GABAB1b are
subunit isoforms that determine pre- and postsynaptic receptor
localization, respectively. Four cytosolic proteins of the KCTD
family (named after their K+-channel tetramerization domain
KCTD8, KCTD12, KCTD12b and KCTD16) associate constitutively
with GABAB2 and function as auxiliary receptor subunits.
3,4 GABAB
receptors exhibit decreased expression in bipolar disorder, major
depressive disorder (MDD) and schizophrenia,5 and have been
proposed as promising treatment targets for these neuropsychia-
tric disorders as well as anxiety and addiction.6–9 In mouse, GABA
B1a and GABAB1b knockout strains have been studied to investigate
the role of GABAB receptors in regulating various behavioral
processes, including activity and innate and conditioned emotion-
ality. Relative to wild-type (WT), GABAB1a - =- mice were mildly more
active during the light phase and GABAB1b - = - mice were
hyperactive during the dark phase.10 There was no clear evidence
for phenotypes in GABAB1a - = - or GABAB1b - = - mice in uncondi-
tioned anxiety tests including elevated plus maze and light–dark
box.11 However, there were marked and speciﬁc phenotypes in
paradigms of conditioned aversion and fear: In conditioned taste
aversion, the characteristics of an otherwise rewarding stimulus
(for example, saccharin solution) are paired with the malaise-
inducing effects of injected lithium chloride such that the reward
is now avoided: GABAB1a - = - mice exhibited a deﬁcit in acquiring
conditioned taste aversion and GABAB1b - =- mice exhibited a deﬁcit
in its extinction.12 Most relevant to the present study, there were
also clear effects of GABAB1 isoforms in a tone-electroshock fear-
conditioning paradigm: GABAB1a - =- mice exhibited normal fear
expression to the conditioned tone but generalization of fear
expression to a neutral tone, and GABAB1b - =- mice exhibited low
fear expression to the conditioned tone consistent with impaired
acquisition or consolidation of fear conditioning.13 Therefore,
GABAB receptors appear to be particularly important in contribut-
ing to the learning and/or memory of conditioned aversive stimuli.
A genome-wide association study of more than 1000 bipolar I
disorder patients identiﬁed a polymorphism in the region of
KCTD12 associated with increased disorder prevalence.14 In a
microarray study comparing probands reporting chronic stress
with matched controls, the former exhibited decreased KCTD12
expression in peripheral blood mononuclear cells (PBMCs).15 A
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translational microarray study of the amygdala in MDD patients
and in mice exposed to unpredictable chronic mild stress
identiﬁed KCTD12/Kctd12 as one of about 30 genes with an
upregulated expression in the amygdala in both MDD patients
and unpredictable chronic mild stress mice relative to their control
groups.16 Microarray studies showed reduced PBMC KCTD12
expression17 and increased postmortem hippocampal expression
of KCTD1218 in schizophrenia patients. In the adult mouse brain,
Kctd12 is expressed highly in hippocampus and amygdala, with
the KCTD12 protein localized primarily postsynaptically4,19 and
associated almost exclusively with GABAB receptors.
20 KCTD12
stabilizes GABAB receptors at the cell surface
3 and regulates
kinetic properties of the receptor response.4 KCTD12 promotes
fast desensitization of GABAB-activated K
+ currents by uncoupling
activated G-protein βγ subunits from effector Kir3 channels.20
Because of its exclusive association with GABAB receptors, a
downregulation of KCTD12 protein is expected to selectively affect
GABAB receptor functions.
20 However, when expressed in excess
of GABAB receptors, free KCTD12 (not associated with GABAB
receptors) will also regulate G-protein signaling of other G-protein
coupled receptors and generate pleiotropic phenotypes.20
In the present study, WT, Kctd12−/− and Kctd12+/− mice were
studied to assess whether KCTD12 regulates phenotypes that
could constitute risk factors (endophenotypes) for neuropsychia-
tric disorders with which KCTD12 downregulation is associated. As
noted above, KCTD12 is associated with psychiatric disorders
including bipolar disorder,14 which is highly (50%) comorbid with
anxiety disorders.21,22 In the depressive phase of bipolar disorder,
as in MDD, increased reactivity to aversive stimuli and reduced
reward interest-pleasure are common, whereas in the manic
phase, increased reward interest-pleasure is common and the day-
night cycle is disrupted resulting in nocturnal hyperactivity.23
Informed by these psychopathologies, we investigated Kctd12−/−
and Kctd12+/− mice in terms of fear learning and memory of an
auditory-conditioned stimulus and of context, locomotion and
innate anxiety, motivation for gustatory reward, and activity levels
across the circadian cycle. We also investigated the electrophy-
siological properties of Kctd12-deﬁcient neurons. Our results
support a role for KCTD12 in the regulation of emotional
learning-memory, activity during the inactive phase, and the
intrinsic electrical excitability of neurons.
MATERIALS AND METHODS
Animals and housing
Male and female Kctd12+/− mice on a C57BL/6 x 129 mixed background
(backcrossed to C57BL/6 for 6 generations)4 were paired to generate
offspring of all 3 genotypes (WT, Kctd12+/− and Kctd12−/−). We conducted
the present experiments with mice that were on the same genetic
background as those used in previous electrophysiological studies.3,20 Mice
were weaned at age 3–4 weeks and males were caged as littermate pairs-
trios. They were maintained on a reversed 12:12 h light–dark cycle (white
light off at 0700 h) in an individually ventilated cage system with
temperature at 20–22 °C and humidity at 50–60%. Food (Complete pellet,
Provimi, Klibad, Kaiseraugst, Switzerland) and water were both available
continuously and ad libitum. Tissue probes for genotyping were obtained
at age 5–7 weeks. There was no effect of genotype on body weight: WT
26.1 ± 0.7 g, Kctd12+/− 27.5 ± 0.8 g, Kctd12−/− 26.6 ± 0.5 g (P= 0.4). All the
procedures were conducted under permits for animal experimentation
issued by the Veterinary Ofﬁce of Zurich or Basel-Stadt, Switzerland.
Genotyping
For genotyping, ear punches or toe clips were incubated overnight at 56 °C
with shaking at 800 r.p.m. in 200 μl lysis buffer containing 50mM KCl,
10mM Tris-HCl (pH 8.3), 2 mM MgCl2, 0.1 mgml
− 1 gelatin, 0.45% NP-40,
0.45% Tween-20 and 0.15mgml− 1 proteinase K (Roche, Rotkreuz,
Switzerland, 03 115 879 001). Following inactivation of proteinase K for
10min at 95 °C and centrifugation for 2 min at 9000 g, 2.0 μl of the
supernatants were used for ampliﬁcation of the 456 bp WT- and 396 bp
knockout-speciﬁc amplicons in two separate PCRs with the following
primers at 0.25 μM: WT, 5′-AAGGAGGTGTTTGGGGACAC-3′ (P2) and 5′-
AGTGGGGTCCAAAGATGATG-3′ (P3); KO, 5′-GATCAGCCTCCTGGAGAAGC-3′
(P1) and 5′-AGTGGGGTCCAAAGATGATG-3′ (P3). REDTaq DNA Polymerase
(Sigma, Buchs, Switzerland, D4309-250UN) was used according to
instructions with the 10 × reaction buffer provided containing 1.5 mM MgCl
2; dNTPs were at 0.2 mM each. The cycling proﬁle was as follows: 94 °C for
2 min, 34 cycles of 94 °C for 1 min, 55 °C for 1 min and 72 °C for 1 min,
followed by a ﬁnal step of 72 °C for 5 min.
Western blotting
Four mice per genotype were decapitated, the brains removed and frozen
on powdered dry ice. Frozen brains were sectioned coronally at 1 mm
intervals using a stainless-steel brain matrix (Plastics One, Roanoke, VA,
USA, model MMCS-1) and single-edge blades (Apollo Herkenrath, Solingen,
Germany, model 10-100-063). Regions of interest, namely medial prefrontal
cortex, amygdala and ventral hippocampus, were microdissected bilat-
erally from the sections using a brain punch (∅= 1mm, Stoelting Europe,
model 57397) and a mouse brain atlas.24 All microdissection steps were
conducted at − 18 °C. Brain biopsies were homogenized in 120 μl ice-cold
NP-40 (Nonidet P-40) buffer (20mM Tris-HCl pH 7.5, 100mM NaCl, 1 mM
EDTA, 0.5% (v/v) NP-40) containing Complete EDTA-free protease inhibitor
cocktail (Roche, 11 836 170 001) using disposable micro-pestles ﬁtting
1.5 ml Eppendorf tubes. Lysis was performed by rocking the tubes for 3 h
at 4 °C. In four mice per genotype, PBMCs were isolated from 1ml blood by
ﬂotation using OptiPrep density gradient medium (Sigma, D1556)
according to the manufacturer’s instructions (Application Sheet C07).
PBMCs (106) were lysed in 100 μl NP-40 buffer for 1 h at 4 °C on a rotating
wheel. For the western blot, lysates were cleared by centrifugation at
16 000 g for 10min at 4 °C and resolved on standard 12% SDS–
polyacrylamide gel electrophoresis. Proteins were transferred to poly-
vinylidene diﬂuoride membranes (Immobilon-P, Millipore, Schaffhausen,
Switzerland, IPVH00010). Membranes were then blocked in 5% bovine
serum albumin in phosphate-buffered saline (PBS) containing 0.1%
Tween-20 (PBST) and probed with the following primary antibodies.
Rabbit anti-KCTD8, rabbit anti-KCTD12, rabbit anti-KCTD16 at 1:2500,19
rabbit anti-KCTD12b (N-terminal peptide MAMPEKSSDVKPTEEC, 1:1000),
mouse anti-GABAB1 (Abcam, AB55051, 1:500), guinea-pig anti-GABAB2
(Millipore, AB5394, 1:2000), all overnight at 4 °C, and mouse anti-tubulin
(BD Pharmingen, Allschwil, Switzerland, Clone 5H1, 1:2500) for 1 h at room
temperature, and peroxidase-coupled secondary antibodies (Amersham
Biosciences, Glattbrugg, Switzerland, NA931V and NA9340V, 1:10 000) for
1 h at room temperature. Primary antibody incubation was in 5% bovine
serum albumin in PBST and secondary antibody incubation was in 5% non-
fat dry milk in PBST. Following antibody incubations, membranes were
washed four times for 10min in PBST. Western blots were visualized using
SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientiﬁc,
Reinach, Switzerland). Images were captured and quantiﬁed under
nonsaturating conditions with a Fusion FX image acquisition system
(Vilber Lourmat, Eberhardzell, Switzerland).
Behavioral tests
Each behavioral experiment was conducted with naive males aged 8–
16 weeks, with mice derived from at least six different litters. Mice were
handled on 3 days before the experiment, and all tests were conducted
between 1100 and 1600 h.
Fear conditioning
The fear-conditioning experiment was conducted using a fully automated
apparatus (MultiConditioning System, TSE Systems, Bad Homburg,
Germany).25 Brieﬂy, the apparatus consisted of a dark-walled Plexiglas
arena (30 × 30 × 24 cm) that was placed on an electriﬁed grid ﬂoor (the
context). A black metal waste tray was placed under the grid ﬂoor. Infrared
light-beam sensors allowed for measurement of movement in three
dimensions. The aversive unconditioned stimulus (US) used was an
electroshock of 2 s × 0.2 mA. The discrete conditioned stimulus (CS) used
was a tone of 5 kHz and 85 dB that was presented for 20 s with the ﬁnal 2-s
contiguous with the US. Four such arenas were used and each was placed
in an attenuating chamber equipped with a ventilation fan and house
lights (8 lux). Mice were tested in either a CS–US or Context–US fear-
conditioning paradigm.
CS–US fear conditioning. This experiment was conducted on three
consecutive days. Day 1, baseline: mice were placed in the arena (context)
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for 15 min without CS or US. Day 2, conditioning: following 2-min
adaptation, mice were exposed to six CS–US pairings with an inter-trial
interval (ITI) of 120 s. On day 1 and day 2, 24 mice per genotype were
included. For the fear expression test on day 3, two different protocols
were used, with 12 mice per genotype allocated to each. Day 3, fear
expression test in same context: after an adaptation time of 180 s, mice
were tested for expression of CS fear using 15× 30 s CS and 14× 90 s ITI.
Day 3, fear expression test in a novel context: mice were tested in a
modiﬁed context with a dark Plexiglas wall containing a door (3.5 (W) × 10
(H) cm) placed across the center of the arena and a white instead of a black
waste tray. The mice were given 180 s adaptation followed by 15× 30 s CS
and 14× 90 s ITI.
Context–US fear conditioning. This experiment was conducted on two
consecutive days, with 12 WT and 12 Kctd12−/− mice. Day 1, conditioning:
mice were given 3 min adaptation followed by 6 × 2 s US and 5× 138 s ITI.
Day 2, fear expression test: in the same context, mice were tested for fear
expression for 18 × 60 s.
In all the cases, freezing was deﬁned as the complete absence of
movement detection for at least 2 s. The output parameters were percent
time spent freezing per CS or ITI. Mean freezing time per mouse was
calculated for each two to three consecutive CSs or ITIs depending on
experiment and phase.
Hot plate
The hot plate pain test was conducted using a programmable thermo-
electric heating plate (Teca, Chicago, IL, USA). The temperature of the hot
plate was set at 50 °C. The mouse was taken out of the home cage, placed
inside a transparent Plexiglas chamber on the hot plate and the lid was
closed. The latency (s) from the ﬁrst contact with the hot plate until the
ﬁrst occurrence of either licking or lifting a forepaw or hindpaw or
jumping, was scored. The maximum test duration was 60 s. Six mice per
genotype were tested.
Open ﬁeld
Mice, 10 per genotype, were placed in the experimental room at 24 h
before testing. The open ﬁeld was a black Plexiglas arena measuring 50
(L) × 50 (W) × 40 (H) cm. Lighting was set to 15 lux at the center. The open
ﬁeld was cleaned and wiped with 70% ethanol before each test. The test
mouse was placed in the center of the arena and location and movement
were monitored using a video-tracking system (VideoMot 2, Version 5.76,
TSE Systems). The ﬂoor was divided virtually into center (30 × 30 cm) and
periphery. The test duration was 30min and data were analyzed in 5-
min bins.
Sucrose preference
The sucrose preference test was conducted in the home cage. Mice, 10 per
genotype, were caged singly at 3 days before the onset of the experiment.
They were habituated to the test bottles (SwissPet, Delphin-Amazonia AG,
Münchenstein, Switzerland) ﬁlled with water, for 3 h on the ﬁrst day and
8 h on the second day. On the following 4 days at 0800–1600 h, mice were
presented with two adjacent bottles, one contained 1% sucrose (Sigma-
Aldrich, CH, St Louis, MO, USA) in water (W/V) and the other contained
water only. The position of the two bottles was reversed daily to control for
side preference. Consumption of sucrose solution and water was
calculated by weighing the bottles at the beginning and end of the 8-h
test. Sucrose preference (%) was calculated as 100× (Δ weight of sucrose
bottle/Δ weight of sucrose bottle+Δ weight of water bottle).
Circadian activity
IntelliCage (NewBehavior, Zurich, Switzerland) is a system for continuous
automated monitoring of the activity of individual mice in their home
cage. Each mouse is ﬁtted with a unique subcutaneous transponder that
records its visits to the operant devices located in each corner of the cage,
its operant nosepokes into a sensor (light-barrier) at the two doors per
corner that open to allow access to drinking bottles, and the number of
drinking licks, measured via electrical contact of the tongue with the tip of
the water bottle cap. The cage of 55 (W) × 38 (L) × 20 (H) cm was divided at
the center to give two independent cages each containing two operant
corner units. Four such divided IntelliCages were used with each placed in
an attenuation chamber with a reversed 12:12 h dark–light cycle and
ventilation. Two male littermates of the same genotype were placed in
each cage-half with access to two corners. Ten mice per genotype were
studied as follows: mice were habituated to the cage for 5 days with
operant doors open, and then 5 days with operant doors closed and one
nosepoke required to open a door for 10 s. Trained mice were then
maintained in the IntelliCage for 20 days and were weighed daily. Output
parameters were the total visits, nosepokes and licks. Data were divided
into a 12-h dark phase and a 12-h light phase.
Electrophysiology
For electrophysiological experiments, 4–6-week-old males and females
were used. Standard procedures were used to prepare 300 μM horizontal
slices. CA1 pyramidal neurons were visualized by Dodt gradient contrast
video microscopy (Luigs and Neumann, Ratingen, Germany) using an
upright microscope (BX51WI, Olympus, Tokyo, Japan) with a × 60/0.9
objective. Slices were superfused continuously with ACSF containing (in
mM): 125 NaCl, 25 NaHCO3, 2.5 KCl, 1.25 NaH2PO4, 2 CaCl2, 1 MgCl2 and 25
glucose (equilibrated with 95% O2–5% CO2). Patch pipettes were pulled
from borosilicate glass (Hilgenberg, Malsfeld, Germany, 2 mm outer and 1
mm inner diameter) using a DMZ-universal puller (Zeitz, Martinsried,
Germany) and ﬁlled with a solution containing (in mM): 140 K-gluconate,
10 HEPES, 2 MgCl2, 2 mM Na2ATP. Pipette resistance was 5.6 ± 0.1 MΩ. The
pipette capacitance was reduced electronically via the ampliﬁer. Series
resistance (14.8 ± 0.1 MΩ) was estimated in bridge mode and compen-
sated. Seal resistance was 9.0 ± 0.6 GΩ. Recordings were accepted if cells
had overshooting action potentials, a Vrest lower than − 60mV and Rin to R
seal ratio o0.1 (P40.5). We used an Axoclamp 700B ampliﬁer (Molecular
Devices, Sunnyvale, CA, USA) and signals ﬁltered and digitalized at 40 and
10 kHz (current and voltage clamp, respectively) using a Digidata 1440A
interface (Molecular Devices).
To isolate the cells synaptically, pharmacological voltage clamp
experiments in CA1 pyramidal neurons were conducted in the presence
of 20 μM 1,2,3,4- tetrahydro-7-nitro-2,3-dioxoquinoxaline-6-carbonitrile
disodium (CNQX), 100 μM picrotoxin (PTX) and 0.5 μM tetrodotoxin (TTX),
to block AMPA/kainate and GABAA receptors as well sodium channels,
respectively. In some experiments, we additionally applied 5 μM CGP54626
to block GABAB receptors. Drugs were kept in H2O stocks at − 20 °C (CNQX,
TTX, BaCl2, CGP54626) or in DMSO stocks at − 20 °C (PTX), diluted 1:1000 in
glucose ACSF and bath applied. We obtained D-AP5, CNQX and TTX from
Ascent Scientiﬁc (Weston-Super-Mare, UK), DTX from Alomone (Jerusalem,
Israel), and all other substances from Sigma-Aldrich.
Data were analyzed using Clampﬁt 10.2 and IgorPro 6.2 (WaveMetrics,
Portland, OR, USA) software. Liquid junction potential was − 10mV and
corrected ofﬂine accordingly. The resting membrane potential (Vrest) was
calculated as the mean of a 10 s trace without current injection
immediately after breakthrough. The current clamp input resistance (Rin)
was the slope of the ﬁt of the IV curve of two hyperpolarizing and two
depolarizing current steps resulting in a voltage deﬂection of o5mV in
current clamp. The voltage clamp input resistance was the slope of the ﬁt
of the IV from±3mV and± 6mV voltage steps. Resting conductance was
the reciprocal of voltage clamp Rin. The barium sensitive resting
conductance was calculated via subtraction of resting conductance in
ACSF and resting conductance in 200 μM Ba2+. The rheobase was deﬁned
as the smallest current inducing at least one action potential within the
ﬁrst 2 s of square current injection. Holding potential for voltage clamp
experiments was − 80mV if not stated otherwise.
Statistical analysis
Behavioral data were analyzed using SPSS (version 19, SPSS, Chicago, IL,
USA). Analysis of variance was used with a between-subject factor of
genotype and, depending on behavioral test, a within-subject factor of
trial. Post hoc testing was conducted using the least signiﬁcant difference
test. Electrophysiological data were analyzed using GraphPad Prism 5.01
(GraphPad, San Diego, CA, USA). In experiments where two sets of data
were obtained from the same cell, results were compared using a Student’s
paired t-test. When two sets of data were obtained from two unpaired
groups, results were analyzed using Student’s t-test. When more than two
sets of data were obtained from two unpaired groups, results were
analyzed using repeated measures analysis of variance with Tukey’s test for
post hoc analysis.
Statistical signiﬁcance was set at Po0.05. Data are presented as
mean± s.e.m. or mean± s.d.
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RESULTS
KCTD12 protein expression in Kctd12-deﬁcient mice
To analyze the consequences of a lack of KCTD12 protein on
behavior and neuronal function we generated Kctd12− /− mice
(Figures 1a and b). Whole-brain lysates of Kctd12− /− mice lacked
KCTD12 protein and had normal levels of GABAB1a, GABAB1b and
GABAB2 protein (Figure 1c). Kctd12
+/− mice had reduced KCTD12
protein levels, indicating that normally both Kctd12 alleles are
transcribed. A compensatory upregulation of another KCTD
auxiliary subunit (KCTD12b, KCTD8 or KCTD16) was not observed
in whole-brain lysates of Kctd12+/− or Kctd12−/− mice (Figure 1c).
Quantitative analysis of KCTD12 protein in amygdala, ventral
hippocampus and prefrontal cortex revealed that Kctd12+/− mice
express ~30–40% of WT protein (Figure 1d). This was replicated
with PBMCs, which provide a biomarker for KCTD12 protein
expression in the brain. Kctd12+/− mice are therefore useful to
analyze the consequences of a partial downregulation of KCTD12
protein in the brain.
Kctd12−/− mice exhibit altered auditory tone-electroshock fear
conditioning and memory
Acquiring and consolidating the information that a discrete CS (for
exmple, auditory tone) is associated with an aversive US (for
example, electroshock), expressed in the form of fear-freezing
behavior, are processes mediated primarily in the amygdala.26
Such fear conditioning is increased in MDD patients27 and in
mouse models of stress-induced depression,28 and is disrupted in
mice lacking GABAB1 subunits.
13 On the basis of this evidence, and
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Figure 1. Generation and characterization of Kctd12-deﬁcient mice. (a) Schematic representation of WT and mutated Kctd12 alleles. The coding
sequence (CDS) of the Kctd12 gene was replaced with a loxP-ﬂanked neomycin resistance cassette (PGKneo) by homologous recombination in
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crossed with a mouse constitutively expressing Cre-recombinase to excise the neomycin cassette, leaving one loxP site behind (Kctd12
knockout allele). PCR primers for genotyping are indicated (P1, P2 and P3). (b) PCR of genomic DNA from Kctd12 WT (+/+), heterozygous (+/− )
and null mutant (−/− ) mice. The sizes of the ampliﬁed PCR products are indicated in base pairs (bp). (c) Western blot showing the absence of
KCTD12 protein in whole-brain lysates of Kctd12− /− mice. Kctd12+/− and Kctd12−/− mice express normal levels of GABAB1 (GB1a,b), GABAB2
(GB2), KCTD12b, KCTD8 and KCTD16 proteins. Equal loading was controlled with anti-tubulin antibodies. (d) Quantitative analysis of KCTD12
protein expression in selected brain regions microdissected from adult brain and in peripheral blood mononuclear cells (PBMCs). Kctd12+/−
mice express 30–40% of WT KCTD12 protein. In PBMC samples KCTD12 runs as a double band, most likely reﬂecting differences in
posttranslational modiﬁcation. Asterisks indicate crossreacting bands. Bar graphs summarize the amount of KCTD12 protein normalized to
tubulin on the same blot (in % of WT). Data are means± s.e.m., n= 4 mice per genotype. GABA, gamma-aminobutyric acid; KCTD, K+-channel
tetramerization domain.
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given that Kctd12 is expressed highly in the amygdala, CS–US fear
conditioning and expression were assessed in Kctd12-
deﬁcient mice.
On day 1, mice were placed in the novel arena (context) without
electroshock to allow for exploration. Mice of each genotype were
active and similarly so, as indicated by the low level of % time
spent freezing (WT 7.3 ± 0.9%, Kctd12+/− 7.5 ± 1.1%, Kctd12−/−
7.8 ± 0.9% (P= 0.95)). On day 2, CS–US conditioning was con-
ducted, and % time spent freezing during CS–US trials and inter-
CS intervals was measured. For % time freezing during CS–US
trials (Figure 2a), there was a main effect of trial number (F
(2,138) = 85.29, Po0.001) indicating acquisition of fear-freezing
across the session. There was also a genotype × trial interaction (F
(4,138) = 4.17, P= 0.003): post hoc analysis revealed that Kctd12−/−
mice exhibited increased fear-freezing in CS–US trials 3–4
compared with WT (Po0.02) and Kctd12+/− (Po0.001) and in
trials 5–6 compared with WT and Kctd12+/− (both Po0.001). For
% time freezing during inter-CS intervals, there was a main effect
of CS–US interval number (F(2,138) = 108.00, Po0.001; Figure 2d),
indicating acquisition of fear-freezing across the intervals between
CS–US pairings. There was also a main effect of genotype (F
(2,69) = 5.15, Po0.008): Kctd12−/−mice exhibited increased fear-
freezing in trials 3–4 compared with WT (Po0.02) and Kctd12+/−
(Po0.01), and in trials 5–6 compared with WT (Po0.02) and
Kctd12+/− (Po0.001). On day 3, the fear expression test was
conducted. For the cohort tested in the same context as used for
CS–US conditioning on day 2, there was a main effect of CS trial
number on % time freezing during the CS (F(4,132) = 6.56,
Po0.001; Figure 2b) indicating a decrease in % time fear-
freezing across trials, but no effect involving genotype (P⩾ 0.43).
For % time freezing during inter-CS intervals (Figure 2e), there was
no effect of CS inter-trial interval number (P= 0.18) and no
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Figure 2. Effects of Kctd12 genotype on fear-conditioned freezing. CS–US fear conditioning: (a–f) Twenty-four mice per genotype underwent
CS–US fear conditioning in a speciﬁc context on day 2 (a and d) and fear expression was then tested in either the same (N= 12, b and e) or a
novel (N= 12, c and f) context on day 3. Freezing during the CS: (a) CS–US conditioning, (b) CS expression test in the same context, (c) CS
expression test in a novel context. Freezing during inter-trial intervals: (d) CS–US conditioning, (e) expression test in the same context, (f)
expression test in a novel context. Context–US fear conditioning (g and h): Twelve mice for each of WT and Kctd12−/− genotypes underwent
(g) context fear conditioning on day 1 and (h) context expression test on day 2. Data are mean± s.e.m. GT, genotype. *Po0.05 for Kctd12−/−
versus WT, ***Po0.001 for Kctd12−/− versus WT. ##Po0.01 for Kctd12−/− versus Kctd12+/− , ###Po0.001 for Kctd12−/− versus Kctd12+/− . CS,
conditioned stimulus; KCTD, K+-channel tetramerization domain; US, unconditioned stimulus; WT, wild type.
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genotype effect (P⩾ 0.55). In the cohort tested for fear expression
in a different context to that used for CS–US conditioning on day
2, there was a main effect of CS trial number on % time freezing
during the CS (F(4, 132) = 5.75, Po0.001; Figure 2c) indicating a
decrease in % time fear-freezing across trials, and no effect of
genotype (P⩾ 0.06). For % time freezing during inter-CS intervals
(Figure 2f), there was a genotype ×CS inter-trial interval interac-
tion (F(8, 132) = 2.30, Po0.03): Kctd12−/− mice exhibited increased
fear-freezing in CS ITIs 1–3 compared with WT (Po0.02) and
Kctd12+/− (Po0.001) and in inter-trial interval 4–6 compared with
WT (Po0.05) and Kctd12+/− (Po0.001). Therefore, the lack of
KCTD12 resulted in increased fear-freezing across CS–US trials.
This did not result in increased next-day fear expression to the CS,
but the Kctd12−/− mice did exhibit increased fear expression
during intervals between CS presentations when placed in a novel
context.
Kctd12−/− mice exhibit normal context–US fear conditioning and
memory
Exposing mice to the aversive US in the arena in the absence of a
CS allowed for the testing of effects of KCTD12 genotype on
emotional learning and memory with respect to contextual or
spatial stimuli. This paradigm also assesses the functioning of the
hippocampus,29 which exhibits altered activity in mood and
anxiety disorders30 and expresses Kctd12 at high levels.19 This
experiment was conducted with Kctd12−/− (N= 12) and WT
(N= 12) mice. During conditioning on day 1, there was a main
effect of US trial number (F(2,44) = 71.25, Po0.001; Figure 2g)
indicating acquisition of fear-freezing across the session, and there
was no effect of genotype (P⩾ 0.71). During the fear expression
test on day 2, there was a main effect of context trial (F
(5,88) = 4.51, Po0.001; Figure 2h) indicating a decrease in fear-
freezing across trials, and there was no effect of genotype
(P⩾ 0.87). Therefore, the involvement of KCTD12 in the regulation
of fear conditioning and memory was speciﬁc to the CS–US
paradigm, which is primarily amygdala mediated, and did not
extend to the context–US paradigm where the hippocampus is
also of importance.
Kctd12−/− mice exhibit normal pain sensitivity
GABAB receptors are involved in the control of pain sensitivity; for
example, the agonist baclofen is antinociceptive31 and GABAB1 - = -
mice exhibit hyperalgesia.32 Because altered pain sensitivity would
impact on behavior in the fear-conditioning tests, where the US
was a painful somatosensory stimulus, it was important to
assess pain sensitivity in KCTD12-deﬁcient mice. There was no
genotype effect on reaction time (in seconds) in the hot plate test:
WT 24.8 ± 5.3, Kctd12+/−28.2 ± 2.5, Kctd12−/− 35.3 ± 4.6 (P= 0.37,
N= 6 per genotype). Therefore, the absence of KCTD12 is not
expected to impact on the sensitivity to the US in the fear-
conditioning tests, and pain sensitivity differences do not explain
the observed effects of KCTD12 on CS–US fear conditioning and
expression.
Kctd12−/− mice exhibit normal locomotor activity and innate
anxiety
The open ﬁeld test was conducted to investigate for effects of
KCTD12 (N= 10 per genotype) on general locomotor activity and
innate anxiety in a novel, neutral environment. The total distance
moved was used as an index of activity, and the distance moved
in the more exposed center was used as a measure of anxiety, that
is, less distance moved in center equates to greater anxiety. Acute
intra-hippocampal injection of classical anxiolytic GABA drugs
decreases anxiety in this test.33 For the total distance moved, there
was a main effect of 5-min time intervals (F(5,135) = 17.78,
Po0.001), with mice exhibiting a consistent reduction in activity
across the 30-min session, as expected for this test. There was no
genotype main effect (P= 0.20) or time-interval interaction
(P= 0.32). For the distance moved in center, there was no
genotype effect (P= 0.20) and no time-interval interaction
(P= 0.21). These ﬁndings indicate that the absence of KCTD12
impacts neither locomotor activity nor innate anxiety in a novel,
neutral environment.
Kctd12−/− mice exhibit normal sucrose preference
The disruptions in interest-pleasure that are symptoms of MDD
and bipolar disorder indicate psychopathology of reward proces-
sing. In rodents, reward sensitivity is typically studied using
gustatory stimuli, with subjects drinking more of a sweet-tasting
sucrose solution than water when a two-bottle choice test is
conducted,34 a preference that is reduced in models of stress-
induced depression.35 Reward processing is mediated by a circuit
that includes GABA signaling between nucleus accumbens, ventral
pallidum and ventral tegmental area, regions that exhibit low-
moderate Kctd12 expression.19 In the present study, mice
exhibited a sucrose preference and this was similar across
genotypes: WT 77± 2%, Kctd12+/− 76 ± 1%, Kctd12−/− 79 ± 2%
(P= 0.41, N= 10 per genotype). Therefore the absence of KCTD12
did not have an impact on gustatory reward processing.
Kctd12+/− mice exhibit increased behavioral activity during the
light (inactive) phase
A distinctive circadian rhythm in terms of amount of activity
during the dark and light phases is a biological norm. Both MDD
and bipolar disorder are characterized by disrupted circadian
rhythm including disturbed sleep or atypically high activity during
the inactive period.23 The IntelliCage system does not provide
data on sleep but does allow for continuous monitoring of activity
in terms of mouse corner visits, operant nosepokes and water
consumption, which in turn can be used to investigate
phenotypes of absolute activity and drinking levels as well as
their circadian distribution. Activity was greater during the 12-h
dark period than the 12-h light period, and this was the case for
each genotype on each measure (Figure 3). For example, for
corner visits, there was a main effect of period (F(1,21) = 113.00,
Po0.001; Figure 3a versus d) in the absence of an effect of
genotype. However, within the light period speciﬁcally, there were
KCTD12-dependent phenotypes. For total number of corner visits,
there was a main effect of genotype (F(2,21) = 4.71, Po0.02):
Kctd12+/−mice made more corner visits than did WT or Kctd12−/
−mice (Figure 3a). There was also a main effect of genotype on
total number of water licks during the light period (F(2,21) = 4.18,
Po0.03): Kctd12+/−mice made more licks than WT and Kctd12−/
−mice (Figure 3c). There was no genotype effect on nosepokes
during the light period (Figure 3b), and also no effects of
genotype were observed during the dark period (Figures 3d and
f). Therefore, downregulation but not complete ablation of
KCTD12 resulted in increased behavioral activity during the
inactive phase speciﬁcally.
KCTD12 activates a tonic K+ resting membrane conductance and
reduces the intrinsic electrical excitability of hippocampal neurons
KCTD12 regulates kinetic properties of GABAB receptor-activated
Ca2+ and K+ currents.3,4 Downregulation of KCTD12 may therefore
inﬂuence neuronal activity. We analyzed the electrophysiological
properties of Kctd12+/− and Kctd12−/− CA1 pyramidal neurons.
These neurons express uniformly high levels of KCTD12 transcripts
and protein4,19 and are easily identiﬁable for electrophysiological
recordings. Patch-clamp experiments using acute hippocampal
slices revealed that the resting membrane potential (Vrest) did not
differ signiﬁcantly between genotypes. However, the input
resistance (Rin) recorded in current clamp was signiﬁcantly higher
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in Kctd12+/− and Kctd12−/− mice compared with WT mice
(Table 1). The simplest explanation for these two observations is
that KCTD12 deﬁciency reduces the number of open ion channels,
and that the ion(s) carried by these channels have an equilibrium
potential at or near the resting potential. Given that KCTD12
regulates the activity of Kir3-type K+ channels,3 the increase in
input resistance likely relates to a decrease in open K+ channels.
An increase in input resistance is expected to inﬂuence the
intrinsic electrical excitability of neurons. Therefore, we next
determined the rheobase current required to evoke action
potentials (AP), which is a measure of the intrinsic excitability of
neurons. When depolarizing neurons in current clamp from Vrest,
we found that the amount of current required to generate at least
one AP was indeed signiﬁcantly reduced in Kctd12+/− and
Kctd12−/− mice compared with WT mice (Figure 4a and Table 1).
In addition, the threshold membrane potential for the generation
of APs (AP threshold), as well as the time from the stimulation to
the peak of the ﬁrst AP (AP delay), were signiﬁcantly different
between Kctd12−/− and WT mice (Table 1). Together, these data
show that the intrinsic electrical excitability of CA1 pyramidal
neurons is increased in mice with no or reduced KCTD12
expression.
The above results may be explained by a decrease in tonic K+
currents in Kctd12−/− and Kctd12+/− neurons. A decrease in tonic
currents will decrease the resting membrane conductance (grest),
which is measured in nano Siemens (nS) and is inversely related to
the input resistance. Voltage-clamp recordings showed that grest
was indeed signiﬁcantly lower in Kctd12−/− than in WT neurons
(Kctd12−/−: 5.1 ± 0.5 nS, n= 11; WT: 7.2 ± 0.5 nS, n= 12; Po0.01).
Surprisingly, however, inhibition of GABAB receptors with the
antagonist CGP54626 did not reduce the resting membrane
conductance in WT neurons to that in Kctd12−/− neurons (WT:
6.7 ± 0.3 nS, n= 21, Kctd12−/−: 5.4 ± 0.4 nS, n= 15, Po0.05). These
results indicate that tonic GABAB receptor activity is not
responsible for the increase in resting conductance in the
presence of KCTD12. We therefore addressed whether indeed K+
channels underlie the KCTD12-induced increase in resting
conductance. Superfusion of slices with 200 μM Ba2+, which
inhibits Kir and K2P-type K+ channels,36,37 signiﬁcantly reduced
the resting membrane conductance of WT neurons to that of
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Figure 3. Effects of Kctd12 genotype on activity and operant drinking behavior in IntelliCage during a 20-day period. Light period 1900–
0700 h: (a) total visits to operant corners, (b) total nosepokes in operant corners, (c) total water licks in operant corners. Dark period 0700–
1900 h: (d) total visits to operant corners, (e) total nosepokes in operant corners, (f) total water licks in operant corners. Values are overall
mean± s.e.m. for 10 mice per genotype. KCTD, K+-channel tetramerization domain; WT, wild type.
Table 1. Passive membrane properties of CA1 pyramidal neurons recorded in acute hippocampal slices
Genotype Membrane potential (mV) Input resistance (MΩ) Rheobase current (pA) AP threshold (mV) AP delay (ms)
WT (n= 61) −69.4± 0.7 283± 13 49.5± 3.5 − 49± 0.6 471± 33
Kctd12+/− (n= 16) − 67.1± 1.3 390± 30** 31.6± 5.2* − 50± 0.6 303± 62
Kctd12−/− (n= 55) − 68.9± 0.5 366± 17*** 30.8± 2.4*** − 52± 0.5** 324±34**
Abbreviations: AP, action potential; KCTD, K+-channel tetramerization domain; WT, wild type. Data are expressed as mean± s.e.m. *Po0.05, **Po0.01,
***Po0.001 (versus WT).
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Kctd12−/− neurons (Figures 4b and d, Po0.01). In line with this,
the Ba2+-sensitive resting conductance determined from the
values in Figure 4d (control minus Ba2+) was signiﬁcantly larger
in WT neurons compared with Kctd12−/− neurons (WT: 2.1 ± 0.2 nS,
Kctd12−/−: 1.2 ± 0.1 nS, n= 16, Po0.01). KCTD12 therefore induces
a tonic Ba2+-sensitive K+ current in the absence of GABAB receptor
activity.
DISCUSSION
Given the importance of GABAB receptors in emotional and
cognitive processing, and the association of human KCTD12 with
neuropsychiatric disorders,14,17,18 we looked for behavioral and
electrophysiological phenotypes in Kctd12 knockout mice. Our
study provides evidence for an involvement of KCTD12 in the
regulation of behavioral phenotypes and the intrinsic electrical
excitability of neurons. Speciﬁcally, homozygous ablation of
Kctd12 led to changes in the fear learning and memory of a
discrete auditory-conditioned stimulus. Heterozygous ablation of
Kctd12 reduced protein expression in blood and brain to ~30–
40%. This genotype led to hyperactivity during the inactive phase
of the circadian cycle speciﬁcally. Kctd12+/− and Kctd12−/− mice
exhibited reduced resting membrane conductances in CA1
pyramidal neurons that reduced the threshold for action potential
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generation. Therefore, homozygous and heterozygous ablation of
Kctd12 in mice lead to speciﬁc behavioral and neuronal
phenotypes that, extrapolating to human, could constitute risk
endophenotypes for the neuropsychiatric disorders associated
with reduced KCTD12 transcription/translation.
In Kctd12+/− mice, the major ﬁnding was hyperactivity during
the light phase of the circadian cycle. In GABAB1 subunit-speciﬁc
knockout mice, relative to WT mice, GABAB1a - = - mice were also
mildly more active during the light phase, whereas GABAB1b - = -
mice were hyperactive during the dark phase.10 The evidence for
increased activity during the normally inactive phase in Kctd12+/−
mice could indicate a deﬁcit in the processes that typically
suppress activity during this stage of the circadian cycle. There is
indeed evidence for involvement of GABAB receptors in circadian
timing; for example, activation of GABAB receptors in the
suprachiasmatic nucleus leads to a shift in circadian phase.38
GABAB receptors also regulate sleep, with the loss of GABAB
receptors delaying the onset of inactivity during the light phase.39
Postsynaptic GABAB receptors are also important in terminating
the persistent activity (‘UP’) states in cortical neuron oscillations
during slow-wave sleep.40 It is noteworthy that resting-state
oscillations occur at a higher frequency and are proposed to
contribute to the network abnormalities observed in bipolar
disorder.41,42 It remains to be understood why a partial reduction
in KCTD12 resulted in this phenotype whereas a complete loss of
KCTD12 did not. As demonstrated, it was not the case that
compensatory changes in expression of other KCTD subunits
occurred in either Kctd12− /− or Kctd12+/− mice.
Kctd12− /− mice, when tested for tone CS-electroshock US fear
conditioning, exhibited phenotypes of suboptimal aversive learn-
ing and memory. They exhibited increased acquisition of fear-
freezing to the CS and during the inter-CS intervals. However, on
the following day, this was not recapitulated as increased
expression of fear to the acquired CS. The Kctd12− /− mice did
exhibit increased fear expression during the inter-CS intervals
when placed in a novel context speciﬁcally. Therefore KCTD12
appears to exert inhibitory modulation of the amount of CS–US
association learning that occurs. It is unusual for an increased
acquisition of fear of a CS not to lead to increased fear expression
to this same CS, suggesting that KCTD12 also contributes to
consolidation of CS–US learning into memory. These data add to
previous reports that GABAB receptors are important regulators of
learning about and/or forming memories of conditioned aversive
stimuli. Increased aversive CS–US fear conditioning is also
exhibited in MDD27 and KCTD12 expression was increased in
amygdala in MDD.16 Together, the ﬁndings suggest that trait or
state changes in KCTD12 levels can contribute to exaggerated
focus on aversive stimuli and events, a common feature of mood
disorder.43
Regarding the neurocircuitry of fear conditioning, CS–US
learning and memory occur primarily in the basal and lateral
nuclei of the amygdala (BLA), and context–US learning and
memory primarily in the hippocampus but dependent on
bidirectional signaling with the BLA.26,44–47 GABA signaling is of
major importance in the local inhibitory circuits that underlie
adaptive CS–US conditioning,48 with GABA interneurons in the
BLA integral to the feed-forward and feedback inhibitory circuits
that control LTP output of the fear projection neurons. Both pre-
and postsynaptic GABAB receptors contribute to this. Studies in
GABAB1a - = - mice have demonstrated that presynaptic GABAB
receptors inhibit postsynaptic LTP in the BLA and thereby prevent
fear generalization.13,29,48 Mice lacking the postsynaptic GABAB1b
subunit exhibit impaired acquisition or consolidation of fear
conditioning.13 Given that Kctd12 is highly expressed in mouse
amygdala and hippocampus,19 and at the cellular level is
expressed primarily postsynaptically,19 it is interesting that the
fear-conditioning phenotypes of Kctd12−/− mice are markedly
different from those of GABAB1b - =- mice.
2 This is consistent with
downregulation or lack of KCTD12 affecting subtle kinetic
properties of postsynaptic GABAB responses
3 rather than prevent-
ing postsynaptic GABAB responses altogether. It is also important
to compare the positive evidence for the importance of GABAB
signaling to adaptive fear learning and memory as obtained with
genetic mouse models, with the recent evidence for the lack of
effects of GABAB agonists and antagonists on mouse fear learning
and memory, using either BALB/c or C57BL/6 strains: GABAB
positive modulators (GS39783, BHF177), the GABAB agonist
baclofen and a GABAB antagonist (CGP52432), were all without
effect on CS–US fear acquisition, recall or extinction.49,50 In rat,
baclofen impaired CS extinction learning.51 Additional experi-
ments are needed to reconcile these discrepancies.
Decreased KCTD12 is expected to affect the precise timing of
GABAB receptor inﬂuences on synaptic transmission and to result
in excessive K+-channel activity, which may cause intracellular K+
depletion and thereby increase neuronal excitability.3,52,53 Here
we show that decreased KCTD12 expression also increases
neuronal excitability by reducing a tonic K+ current. Surprisingly,
the KCTD12-induced tonic current does not depend on GABAB
receptor activation. Since KCTD12 directly regulates the activity of
heterotrimeric G-protein subunits,3 it may induce tonic K+ currents
by activating the G-protein in the absence of receptor activity.
Alternatively, KCTD12 may directly bind and activate effector K+
channels. Lack of KCTD12 therefore increases neuronal excitability
through synaptic and intrinsic mechanisms, which could be
contributory to the suboptimal CS fear learning and memory
observed in Kctd12−/− mice.
Given the human evidence for association of KCTD12 with
bipolar disorder, MDD and schizophrenia, the current ﬁndings that
Kctd12+/− and Kctd12− /− mice exhibit behavioral phenotypes of
altered emotional and homeostatic behaviors and that these co-
occur with increased excitability of hippocampal neurons,
constitutes cause–effect evidence for the neurobehavioral impor-
tance of KCTD12. Of course, altered KCTD12 expression would be
one speciﬁc factor in the complex gene–environment interactions
that underlie the etiopathophysiology of these neuropsychiatric
disorders. This study makes an important contribution to the
animal model evidence that is essential to allow accurate
assessment of GABAB receptors as a potential target for the
treatment of neuropsychiatric domains, both within and across
some of the major disorders.
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